| Species |
Human |
| Protein Construction |
Calprotectin (S100A8 & S100A9) [Met1-Glu93 (S100A8) & Thr2-Pro114 (S100A9)]
Accession # P05109 (S100A8) & P06702 (S100A9) |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
E.coli |
| Theoretical Molecular Weight |
11.7 kDa(S100A8)&13.2 kDa(S100A9) |
| Apparent Molecular Weight |
The protein has a predicted MW of 11.7 kDa(S100A8)&13.2 kDa(S100A9) same as Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in 2mM DTT, PBS (pH 7.2). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Calprotectin, a member of the widespread calcium-binding S-100 protein family, is present in remarkably high concentration in the cytoplasm of human neutrophils. The calprotectin molecule is composed of light (MRP8) and heavy (MRP14) subunits. Although not secreted from intact neutrophils, calprotectin release from dead and dying neutrophils creates high concentrations of the protein in inflammatory or abscess fluids and in the intestinal tract lumen of patients with inflammatory bowel disease. |
| Synonyms |
Protein S100-A8;Calgranulin-A;CFAG;MRP-8;S100 calcium-binding protein A8;Protein S100-A9;MRP-14;S100 calcium-binding protein A9 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
